**Fig. 1**


p<0.0001
n.s.
⇩7%
⇩95%
⇩85%
⇩94%
⇩87%
CD11b (MFI)
16000
12000
8000
4000
0
HBSS (Buffer Control)
IgG4 control (16.7 nM)
IFX-1 lot 004 (16.7 nM)
IFX-1 lot 012 (16.7 nM)
rhC5a (16.7 nM)
IgG4 control : rhC5a = 1:1
IFX-1 lot 004 : rhC5a = 1:1
IFX-1 lot 004 : rhC5a = 0.5:1
IFX-1 lot 012 : rhC5a = 1:1
IFX-1 lot 012 : rhC5a = 0.5:1

**Fig. 2**


1800
1500
1200
900
600
300
0
CD11b (MFI)
p<0.0001
⇩ 100%
⇩ 100%
⇩ 98%
⇩ 98%
⇩ 82%
NaCl (Buffer Control)
IFX-1
ZAP (5 µl)
IFX-1 : ZAP = 4:1
IFX-1 : ZAP = 3:1
IFX-1 : ZAP = 2:1
IFX-1 : ZAP = 1:1
IFX-1 : ZAP = 0.5:1

**Fig. 3**


20000
15000
10000
5000
0
CD11b (MFI)
p<0.0001
p<0.0001
⇩100%
⇩93%
⇩90%
⇩79%
HBSS (Buffer Control)
rhC5a (16.7 nM)
IFX-1:rhC5a= 1:1
zymosan (100 µg/ml)
IFX-1 (24 nM)
IFX-1 (12 nM)
IFX-1 (6 nM)
IFX-1 + zymosan A (100 µg/ml)
containing ~ 6 nM eC5a

**Fig. 4**


4000
3000
2000
1000
0
IL-8 conc. [pg/ml]
with IFX-1 [200 nM]
w/o IFX-1 [200 nM]
0
20
40
100
200
400
Zymosan A [µg/ml]

**Fig. 5**

**A**


C3a
25000
20000
15000
10000
5000
0
ng/ml
p: 0.003
Controls
HS

**B**


C5a
100
80
60
40
20
0
ng/ml
p: 0.006
Controls
HS

C



**Fig. 6**


Plasma ID | hu-007 | ctrl008 | ctrl012 | pat088 | pat092
C5a [ng/ml] | 21.26 | 25.43 | 10.12 | 93.77 | 70.01
CD11b FITC [MFI]
20000
15000
10000
5000
0
100%
100%
102%
100%
102%
102%
background (saline)
huPP-007
huPP-007 + 20 nM rhC5a
huPP-007 + 20 nM rhC5a + 20 nM IFX-1
ctrl008
ctrl012
pat088
pat088 + 5 nM IFX-1
pat088 + 20 nM IFX-1
pat088 + 50 nM IFX-1
pat092
pat092 + 5 nM IFX-1
pat092 + 20 nM IFX-1
pat092 + 50 nM IFX-1

**Fig. 7**


HiSCR Response
80%
70%
60%
50%
40%
30%
20%
10%
0%
0%
0%
55%
45%
64%
73%
week 1 (n=12)
week 4 (n=11)
week 5 (n=11)
week6 (n=11)
week 7 (n=11)
week 8 (n=11)

**Fig. 8**


in-study controls using human plasma pool
plasma from healthy volunteers and HS-disease patients
CD11b MFI
10000
8000
6000
4000
2000
0
73%
71%
73%
76%
76%
79%
Saline
huPP
huPP | Clone S5/1 (50 nM)
huPP | Clone 7H110 (50 nM)
huPP | rhC5a (20 nM)
huPP | rhC5a | Clone S5/1 (50 nM)
huPP | rhC5a | Clone 7H110 (50 nM)
Ctrl 010
Ctrl 009
Pat. 088
Pat. 088 | Clone S5/1 (50 nM)
Pat. 088 | Clone 7H110 (50 nM)
Pat. 092
Pat. 092 | Clone S5/1 (50 nM)
Pat. 092 | Clone 7H110 (50 nM)

**Fig. 9**

**A**


in-study controls using human plasma pool
plasma from healthy volunteers and HS-disease patients
CD11b MFI
10000
8000
6000
4000
2000
0
50%
55%
57%
Saline
huPP
huPP | PMX-53 (50 nM)
huPP | rhC5a (20 nM)
huPP | rhC5a | PMX-53 (50 nM)
Ctrl 010
Ctrl 009
Pat. 088
Pat. 088 | PMX-53 (50 nM)
Pat. 092
Pat. 092 | PMX-53 (50 nM)

**B**


in-study controls using
human plasma pool
plasma from healthy volunteers
and HS-disease patients
CD11b MFI
10000
8000
6000
4000
2000
0
108%
104%
109%
Saline
huPP
huPP | PMX-53 (20 µM)
huPP | rhC5a (20 nM)
huPP | rhC5a | PMX-53 (20 µM)
Ctrl 010
Ctrl 009
Pat. 088
Pat. 088 | PMX-53 (20 µM)
Pat. 092
Pat. 092 | PMX-53 (20 µM)

**Fig. 10**


in-study controls using
human plasma pool
plasma from healthy volunteers
and HS-disease patients
CD11b MFI
10000
8000
6000
4000
2000
0
103%
102%
104%
Saline
huPP
huPP | IFX-1 (20 nM)
huPP | rhC5a (20 nM)
huPP | rhC5a | IFX-1 (20 nM)
Ctrl 010
Ctrl 009
Pat. 088
Pat. 088 | IFX-1 (20 nM)
Pat. 092
Pat. 092 | IFX-1 (20 nM)

**Fig. 11**


in-study controls
plasma from healthy volunteers and HS-disease patients
CD11b MFI
14000
12000
10000
8000
6000
4000
2000
0
77%
105%
80%
104%
Saline
huPP
Ctrl 010
Ctrl 009
Pat. 088
Pat. 088 | Avacopan (100 µM)
Pat. 088 | Avacopan (500 µM)
Pat. 092
Pat. 092 | Avacopan (100 µM)
Pat. 092 | Avacopan (500 µM)